Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
From the Brain & Mind Centre (J.B., T.A.H., S.W.R., M.H.B.), University of Sydney; Neuroimmunology Clinic (T.A.H., S.R., S.W.R.), Concord Repatriation General Hospital, Sydney; Sydney Neuroimaging Analysis Centre (Y.B., M.H.B.); St Vincent's Hospital (Y.B.), Sydney, Australia; and Addenbrookes Hospital (A.C.), University of Cambridge, UK.
Joshua
J
Barton
From the Brain & Mind Centre (J.B., T.A.H., S.W.R., M.H.B.), University of Sydney; Neuroimmunology Clinic (T.A.H., S.R., S.W.R.), Concord Repatriation General Hospital, Sydney; Sydney Neuroimaging Analysis Centre (Y.B., M.H.B.); St Vincent's Hospital (Y.B.), Sydney, Australia; and Addenbrookes Hospital (A.C.), University of Cambridge, UK.
Todd A
TA
Hardy
From the Brain & Mind Centre (J.B., T.A.H., S.W.R., M.H.B.), University of Sydney; Neuroimmunology Clinic (T.A.H., S.R., S.W.R.), Concord Repatriation General Hospital, Sydney; Sydney Neuroimaging Analysis Centre (Y.B., M.H.B.); St Vincent's Hospital (Y.B.), Sydney, Australia; and Addenbrookes Hospital (A.C.), University of Cambridge, UK.
Sean
S
Riminton
From the Brain & Mind Centre (J.B., T.A.H., S.W.R., M.H.B.), University of Sydney; Neuroimmunology Clinic (T.A.H., S.R., S.W.R.), Concord Repatriation General Hospital, Sydney; Sydney Neuroimaging Analysis Centre (Y.B., M.H.B.); St Vincent's Hospital (Y.B.), Sydney, Australia; and Addenbrookes Hospital (A.C.), University of Cambridge, UK.
Stephen W
SW
Reddel
From the Brain & Mind Centre (J.B., T.A.H., S.W.R., M.H.B.), University of Sydney; Neuroimmunology Clinic (T.A.H., S.R., S.W.R.), Concord Repatriation General Hospital, Sydney; Sydney Neuroimaging Analysis Centre (Y.B., M.H.B.); St Vincent's Hospital (Y.B.), Sydney, Australia; and Addenbrookes Hospital (A.C.), University of Cambridge, UK.
Yael
Y
Barnett
From the Brain & Mind Centre (J.B., T.A.H., S.W.R., M.H.B.), University of Sydney; Neuroimmunology Clinic (T.A.H., S.R., S.W.R.), Concord Repatriation General Hospital, Sydney; Sydney Neuroimaging Analysis Centre (Y.B., M.H.B.); St Vincent's Hospital (Y.B.), Sydney, Australia; and Addenbrookes Hospital (A.C.), University of Cambridge, UK.
Alasdair
A
Coles
From the Brain & Mind Centre (J.B., T.A.H., S.W.R., M.H.B.), University of Sydney; Neuroimmunology Clinic (T.A.H., S.R., S.W.R.), Concord Repatriation General Hospital, Sydney; Sydney Neuroimaging Analysis Centre (Y.B., M.H.B.); St Vincent's Hospital (Y.B.), Sydney, Australia; and Addenbrookes Hospital (A.C.), University of Cambridge, UK. michael@sydneyneurology.com.au.
Michael H
MH
Barnett
D000328:Adult; D000074323:Alemtuzumab / Q000009:adverse effects*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D001921:Brain / Q000000981:diagnostic imaging; D003711:Demyelinating Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000000981:diagnostic imaging / Q000188:drug therapy
D000074322:Antineoplastic Agents, Immunological; D000074323:Alemtuzumab